ALLO-501A
ALLO-501A-201
Phase 2 gene_therapy active
Quick answer
ALLO-501A for Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma is a Phase 2 program (gene_therapy) at Allogene Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Allogene Therapeutics
- Indication
- Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active